Catalog No. |
TD-HW338036 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG4 |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
FLK-1, Kinase insert domain receptor, VEGFR2, Fetal liver kinase 1, CD309, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, FLK1, VEGFR-2, KDR |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P35968 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Background |
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/Flk-1/VEGFR2/KDR/Flk-1/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001). |
Note |
For research use only. Not for use in clinical or therapeutic applications. |